NEW DELHI: GlaxoSmithKline Pharma, in its centenary yr in India, is remodeling right into a specialty-driven firm and constructing a preventive healthcare ecosystem led by grownup vaccines. Because the nation’s second-largest drug MNC with almost 30 crore prescriptions yearly, GSK Pharma plans to enter the oncology market with the launch of two main high-value therapies, increasing past its legacy choices generally drugs, its managing director, Bhushan Akshikar, informed TOI.
Moreover, the Rs 3,500 crore firm will widen its preventive portfolio by introducing extra grownup vaccines, shifting the main focus from conventional toddler immunisation to complete preventive healthcare for all ages.
“We stay rooted in our goal to convey innovation at scale, and with influence,” Akshikar, who completes two years on the helm, mentioned.
“After our renewed focus as a biopharma firm globally, now we have rejigged and contemporised our portfolio right here, and development is now led by innovation. Additionally, newer therapies are firing up gross sales,” he mentioned.
Elaborating on the pricing technique, he mentioned, “we have at all times had tiered pricing in India. When you take a look at our complete portfolio, whether or not it’s common medicines, the place we function with a commoditised class like paracetamol, and but now we have a model like Calpol, in the identical worth band.” (Paracetamol is a part of the Nationwide Checklist of Important Medicines and worth management)
